CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The IMPACTT project aims to develop and test a novel therapy using Anti-Pseudomonas Immunoglobulin Y to prevent and treat chronic lung infections caused by Pseudomonas aeruginosa in cystic fibrosis patients. This innovative approach seeks to improve patient quality of life and reduce the impact of severe respiratory co…
Cystic Fibrosis (CF) is a chronically debilitating and life threatening medical condition.
Respiratory insufficiency and complications of chronic lung infection lead to long term reduction in quality of life and health and even to premature death.
Chronic bacterial infections with Pseudomonas aeruginosa (PA), Staphylococcus aureus and Haemophilus influezae are typical for CF and repeated courses of antibiotics in heavy doses has more than doubled the median survival age.
No preventive or eradica…
UPPSALA UNIVERSITET
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Sweden, UPPSALA
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Denmark, Hillerod
Type: Public body
Activity type: Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
